Suchergebnisse - "Lathouwers, Erkki"

PubPharm (34)

1

Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials

enthalten in: Journal of medical virology | 2021

von Lathouwers, E. | Weinsteiger, S. | Baugh, B. | +5

2

Week 96 resistance analyses of the once‐daily, single‐tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV‐1 from the phase 3 randomized AMBER and EMERALD trials

enthalten in: Journal of Medical Virology | 2021

von Lathouwers, E. | Weinsteiger, S. | Baugh, B. | +5

3

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

enthalten in: HIV research & clinical practice | 2020

von Huhn, G. | Wilkin, A. | Mussini, C. | +8

4

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

enthalten in: HIV research & clinical practice | 2020

von Lathouwers, E. | Seyedkazemi, S. | Luo, D. | +3

5

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

enthalten in: AIDS (London, England) | 2020

von Orkin, C. | Eron, J. | Rockstroh, J. | +9

6

Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials

enthalten in: AIDS research and human retroviruses | 2020

von Lathouwers, E. | Wong, E. | Brown, K. | +108

7

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

enthalten in: Antiviral research | 2019

von Eron, J. | Orkin, C. | Cunningham, D. | +111

8

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1 : subgroup analyses of the phase 3 EMERALD study

enthalten in: AIDS research and therapy | 2019

von Huhn, G. | Eron, J. | Girard, P. | +10

9

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

enthalten in: AIDS research and therapy | 2019

von Huhn, G. | Eron, J. | Girard, P. | +10

10

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study

enthalten in: AIDS research and therapy | 2019

von Huhn, G. | Eron, J. | Girard, P. | +10